keyword
MENU ▼
Read by QxMD icon Read
search

Intraperitoneal chemotherapy

keyword
https://www.readbyqxmd.com/read/28089175/reduction-of-carcinomatosis-risk-using-icodextrin-as-a-carrier-solution-of-intraperitoneal-oxaliplatin-chemotherapy
#1
I Jouvin, H Najah, C Pimpie, C Canet Jourdan, R Kaci, M Mirshahi, C Eveno, M Pocard
There is no standard treatment in patients with high risk metachronous peritoneal carcinomatosis (PC) in colonic cancer, as perforated tumour or synchronous ovarian metastasis. Icodextrin 4% (ICDX), presently used to prevent postoperative abdominal adhesions, could inhibit the coactivation of the tumour cells and the microenvironment cells, associated with the development of PC. The aim of this study was to inhibit the formation of the PC in a murine model mimicking surgical situation using ICDX and intraperitoneal (IP) prophylactic chemotherapy...
January 9, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28078127/prophylactic-hyperthermic-intraperitoneal-chemotherapy-can-be-considered-in-the-management-of-advanced-gastric-cancer
#2
Antonio Macrì, Edoardo Saladino
No abstract text is available yet for this article.
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28075611/what-the-radiologist-should-know-about-treatment-of-peritoneal-malignancy
#3
Emily A Aherne, Helen M Fenlon, Conor J Shields, Jurgen J Mulsow, Carmel G Cronin
OBJECTIVE: The purpose of this article is to discuss the role of the radiologist in the treatment of peritoneal cancer, with focus placed on advanced treatment options and selection of patients with resectable disease for whom complete cytoreduction can be achieved. CONCLUSION: Peritoneal cancers traditionally have been associated with significant morbidity and universal mortality; however, the management of such cancers has evolved substantially. Advanced treatment options, including cytoreductive surgery and intraperitoneal chemotherapy, are associated with significantly improved long-term patient survival...
January 11, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28072694/effect-of-hyperthermic-intrathoracic-chemotherapy-hithoc-on-the-malignant-pleural-effusion-a-systematic-review-and-meta-analysis
#4
Hua Zhou, Wei Wu, Xiaoping Tang, Jianying Zhou, Yihong Shen
BACKGROUND: Although hyperthermic intraperitoneal chemotherapy (HIPEC) has been widely used to treat malignant ascites or as a preventive strategy for microscopic carcinomatosis following surgical resection of abdominal tumors, application of hyperthermic intrathoracic chemotherapy (HITHOC) in the treatment of malignant pleural effusion is limited. The objective of the current study was to conduct a systematic review and meta-analysis on the application of HITHOC in the palliative treatment of malignant pleural effusion...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28068634/virgin-coconut-oil-supplementation-attenuates-acute-chemotherapy-hepatotoxicity-induced-by-anticancer-drug-methotrexate-via-inhibition-of-oxidative-stress-in-rats
#5
Ademola C Famurewa, Odomero G Ufebe, Chima A Egedigwe, Onyebuchi E Nwankwo, Godwin S Obaje
BACKGROUND: The emerging health benefit of virgin coconut oil (VCO) has been associated with its potent natural antioxidants; however, the antioxidant and hepatoprotective effect of VCO against methotrexate-induced liver damage and oxidative stress remains unexplored. The study explored the antioxidant and hepatoprotective effects of VCO against oxidative stress and liver damage induced by anticancer drug methotrexate (MTX) in rats. METHODS: Liver damage was induced in Wistar rats pretreated with dietary supplementation of VCO (5% and 15%) by intraperitoneal administration of MTX (20mg/kg bw) on day 10 only...
January 6, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28061769/intraperitoneal-cisplatin-and-doxorubicin-as-maintenance-chemotherapy-for-unresectable-ovarian-cancer-a-case-report
#6
Clemens B Tempfer, Franziska Hartmann, Ziad Hilal, Günther A Rezniczek
BACKGROUND: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. CASE PRESENTATION: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC)...
January 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28059968/multicenter-phase-ii-study-of-intravenous-and-intraperitoneal-paclitaxel-with-s-1-for-pancreatic-ductal-adenocarcinoma-patients-with-peritoneal-metastasis
#7
Sohei Satoi, Tsutomu Fujii, Hiroaki Yanagimoto, Fuyuhiko Motoi, Masanao Kurata, Naminatsu Takahara, Suguru Yamada, Tomohisa Yamamoto, Masamichi Mizuma, Goro Honda, Hiroyuki Isayama, Michiaki Unno, Yasuhiro Kodera, Hironori Ishigami, Masanori Kon
OBJECTIVE: To evaluate the clinical efficacy and tolerability of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel combined with S-1, "an oral fluoropyrimidine derivative containing tegafur, gimestat, and otastat potassium" in chemotherapy-naive pancreatic ductal adenocarcinoma (PDAC) patients with peritoneal metastasis. BACKGROUND: PDAC patients with peritoneal metastasis (peritoneal deposits and/or positive peritoneal cytology) have an extremely poor prognosis...
February 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28058545/the-role-of-neoadjuvant-and-adjuvant-systemic-chemotherapy-with-cytoreductive-surgery-and-heated-intraperitoneal-chemotherapy-for-colorectal-peritoneal-metastases-a-systematic-review
#8
Kathryn Waite, Haney Youssef
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is an effective treatment for colorectal peritoneal metastases (CPM), increasing overall survival in selected patients. The aim of this systematic review was to assess the effect of neoadjuvant and adjuvant systemic chemotherapy on overall survival in patients with CPM undergoing CRS and HIPEC, compared with those who receive CRS and HIPEC alone. METHODS: A systematic literature review was performed using the PubMed database, and the preferred reporting items for systematic reviews and meta-analyses guidelines formed the structure of the review...
January 5, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28055083/physiologic-response-to-hipec-sifting-through-perturbation-to-identify-markers-of-complications
#9
Timothy P Plackett, Hieu H Ton-That, Michael J Mosier, Gerard J Abood, Paul C Kuo, Sam G Pappas
CONTEXT: The postoperative physiologic response to hyperthermic intraperitoneal chemotherapy (HIPEC) has been poorly studied outside of the immediate perioperative time. OBJECTIVE: To characterize the physiologic response during the first 5 days after HIPEC and identify variables associated with major complications. METHODS: Patients undergoing HIPEC and cytoreductive surgery during a 14-month interval were retrospectively identified and their records reviewed for demographics, physiologic response, and major complications...
January 1, 2017: Journal of the American Osteopathic Association
https://www.readbyqxmd.com/read/28054141/indications-for-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-elderly-patients-with-peritoneal-malignancy
#10
Toshiyuki Kitai, Kenya Yamanaka, Yuya Miyauchi, Masahiro Kawashima
PURPOSE: A combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is effective for some peritoneal malignancies. However, the indications for elderly patients remain unclear, with substantial postoperative morbidity and mortality being problematic. MATERIALS: Clinical data were analyzed in 42 patients undergoing CRS + HIPEC for peritoneal malignancy. The primary tumor was located in the appendix in 32 cases and elsewhere in 10 cases...
January 4, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28052691/strategies-to-prevent-peritoneal-carcinomatosis-arising-from-colorectal-cancer
#11
Maximiliano Gelli, Janina Fl Hugueinin, Cecilia Cerebelli, Léonor Benhaim, Charles Honoré, Dominique Elias, Diane Goéré
In the last decades, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy became a curative option for peritoneal metastases in selected patients, otherwise considered for palliative therapy alone. Better knowledge of physiopathology of peritoneal spread and identification of predictive factors for peritoneal relapse prompted specialized centers to investigate the role of a 'proactive approach' in order to early detect peritoneal metastasis. These encouraging data could justify an active attitude in selected patients at high risk of peritoneal recurrence after curative resection of primary tumor...
January 5, 2017: Future Oncology
https://www.readbyqxmd.com/read/28041630/the-analgesic-effect-of-orexin-a-in-a-murine-model-of-chemotherapy-induced-neuropathic-pain
#12
Satoshi Toyama, Naohito Shimoyama, Megumi Shimoyama
Orexins are neuropeptides that are localized to neurons in the lateral and dorsal hypothalamus but its receptors are distributed to many different regions of the central nervous system. Orexins are implicated in a variety of physiological functions including sleep regulation, energy homeostats, and stress reactions. Furthermore, orexins administered exogenously have been shown to have analgesic effects in animal models. A type of intractable pain in patients is pain due to chemotherapy-induced peripheral neuropathy (CIPN)...
December 24, 2016: Neuropeptides
https://www.readbyqxmd.com/read/28039716/hyperthermic-intraperitoneal-chemotherapy-plus-high-frequency-diathermic-therapy-followed-by-intravenous-chemotherapy-versus-intravenous-chemotherapy-alone-for-postoperative-adjuvant-treatment-of-gastrointestinal-cancer-a-comparative-research-study
#13
Li-Zhen Gao, E-Mei Gao, Yun-Fei Bai, Hai-Long Su, Fan Zhang, Mei-Qing Ge, Dong-Lian Liu, Yan-Kun Huang
PURPOSE: To evaluate the therapeutic efficacy and toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) plus high-frequency diathermic therapy (HFDT) followed by intravenous chemotherapy vs intravenous chemotherapy alone for adjuvant treatment of postoperative gastrointestinal neoplasms. METHODS: Fifty-two gastrointestinal carcinoma patients who were radically operated were enrolled and divided into the treatment group and the control group. In the treatment group, 25 patients were treated with combination of HIPEC+HFDT and subsequent intravenous chemotherapy, while in the control group 27 patients received intravenous chemotherapy alone...
November 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28033247/outcomes-of-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-colorectal-cancer-with-peritoneal-metastasis
#14
En-Kwang Lin, Mao-Chih Hsieh, Chien-Hsin Chen, Yen-Jung Lu, Szu-Yuan Wu
In Taiwan, colorectal cancer with peritoneal carcinomatosis is considered a terminal condition. We examined the clinical outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) treatment for colorectal cancer with peritoneal carcinomatosis in Taiwan.We enrolled patients with colorectal cancer and peritoneal metastasis from Taipei Medical University, Wanfang Hospital between January 1999 and December 2014. Of the enrolled patients, 3 had mucinous-type tumors. In total, we enrolled 31 patients who underwent a total of 33 procedures...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28029523/cytoreduction-and-hyperthermic-intraperitoneal-chemotherapy-cs-hipec-in-colorectal-cancer-evidence-based-review-of-patient-selection-and-treatment-algorithms
#15
REVIEW
A H Maciver, N Lee, J J Skitzki, P M Boland, V Francescutti
Cytoreduction and heated intraperitoneal chemotherapy (CS/HIPEC) is increasingly utilized as a treatment strategy for patients with peritoneal metastases from various primary tumor sites. For this heterogenous procedure, related to patient characteristics, patient selection, and the extent of surgical completeness of cytoreduction, high level evidence (ex: multiple randomized controlled trials) is not available to support efficacy. This review of the available literature supporting application of the procedure, focusing on colorectal cancer, provides a summary of current evidence for patient selection and treatment algorithms based on patient presentation...
October 3, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28028665/surgery-after-intraperitoneal-and-systemic-chemotherapy-for-gastric-cancer-with-peritoneal-metastasis-or-positive-peritoneal-cytology-findings
#16
Hironori Ishigami, Hironori Yamaguchi, Hiroharu Yamashita, Masahiro Asakage, Joji Kitayama
BACKGROUND: Despite recent progress in systemic chemotherapy, the prognosis of gastric cancer patients with peritoneal metastasis (P1) or positive peritoneal cytology findings (CY1) is still poor. We developed a regimen combining intraperitoneal (IP) paclitaxel (PTX) with S-1 and PTX, which can produce notable efficacy with regard to peritoneal lesions. Surgery after response to combination chemotherapy is a promising option for P1 or CY1 gastric cancer. A retrospective study was performed to evaluate the safety and efficacy...
December 27, 2016: Gastric Cancer
https://www.readbyqxmd.com/read/28028374/-en-bloc-caudate-lobe-and-inferior-vena-cava-resection-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-and-liver-metastasis-of-colorectal-cancer
#17
Patricia Sánchez-Velázquez, Nicolas Moosmann, Ingolf Töpel, Pompiliu Piso
There are diverse protocols to manage patients with recurrent disease after primary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis. We describe a case of metachronous liver metastasis after CRS and HIPEC for colorectal cancer, successfully treated with a selective metastectomy and partial graft of the inferior vena cava. A 35-year-old female presented with a large tumour in the cecum and consequent colonic stenosis. After an emergency right colectomy, the patient received adjuvant chemotherapy...
December 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28028255/-a-new-treatment-strategy-novel-cell-free-and-concentrated-ascites-reinfusion-system-km-cart-for-massive-malignant-ascites
#18
Keisuke Matsusaki
Massive ascites associated with cancerous peritonitis can result in severe respiratory discomfort and abdominal fullness. Additionally, it can significantly impair the activities of daily living of a patient, and relaxation is difficult to achieve, even with opioids. Frequent ascites drainage can cause rapid worsening of the patient's general condition, and a large amount of ascites can lead to discontinuation of anti-cancer treatment. Cell-free and concentrated ascites reinfusion therapy(CART)for refractory ascites was first covered by the insurance system in 1981...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28028253/-intraperitoneal-chemotherapy-for-peritoneal-metastasis-of-gastric-cancer
#19
Hironori Yamaguchi, Hironori Ishigami, Joji Kitayama
Peritoneal metastasis of gastric cancer remains a refractory disease, and the standard treatment strategy is still unclear. Intraperitoneally administered paclitaxel(PTX)remains in the intraperitoneal(IP)cavity for a long time and directly infiltrates peritoneal metastatic nodules, thereby producing antitumor effects. We designed an IP chemotherapy regimen of S-1 combined with weekly intravenous(IV)and IP PTXadministration. In our phase I study, the recommended dose of IP PTXwas determined to be 20mg/m2. In our phase II study for patients with P1(macroscopic peritoneal metastasis-positive)or CY1 (cytology-positive)gastric cancer, the 1-year overall survival(OS)rate was 78%and the median survival time(MST)was 23...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28028252/-chemotherapeutic-strategies-for-peritoneal-dissemination-of-gastric-cancer
#20
Tomohiro Matsushima, Takeru Wakatsuki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi
The prognosis of unresectable or metastatic gastric cancer is poor. One of the reasons for this is peritoneal dissemination, which is often observed in gastric cancer. Here, we discuss some new therapeutic strategies, especially chemotherapeutic strategies, for peritoneal dissemination of gastric cancer. Occasionally, in cases of peritoneal dissemination, patients have severe ascites or bowel obstruction. For those who have such complications, treatment via chemotherapy including S-1, capecitabine, or cisplatin is inappropriate...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
63283
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"